Bicalutamide (Casodex®)

Common name: Bicalutamide
Brand name: Casodex®
 

What is Bicalutamide?

Bicalutamide is a non-steroidal anti-androgen used to treat advanced (metastatic) prostate cancer. It works by reducing the amount of testosterone in the body.  Bicalutamide may be given in combination with other hormonal therapies such as luteinizing hormone releasing hormone (LHRH) analogues or in the surgical removal of the testicles (castration).
 

How is Bicalutamide administered?

Bicalutamide is administered orally as a tablet.
 

What are possible side effects of this treatment?

Everyone responds differently to hormone therapy – some experience many side effects while others experience very few. Below are some side effects experienced by those who received bicalutamide. Tell your health care team about side-effects you are experiencing so they know how best to help you manage them.
 
  • Constipation
  • Decreased libido
  • High blood pressure
  • Hot flashes
  • Impotence (erectile dysfunction)
  • Loss of appetite
  • Nausea
  • Muscle weakness
  • Swelling of breasts
 

Is Bicalutamide covered in my province or territory?

Bicalutamide is covered by all provincial/territorial drug programs.


 
Last Reviewed: July 2017

Donate Now!






Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
$2 million invested in new prostate cancer research

Prostate Cancer Canada and Movember partner to fund ten research projects breaking new ground
More

Dream car draw a win for all Ontarians affected by prostate cancer

February 22, 2019 – TORONTO, ON – A dream came true today for Harold Mutter (ticket #19273), the lucky winner of a 2018 Acura NSX valued at more than $235,000 - the prize for Prostate Cancer Canada’s seventh Rock the Road Raffle.
More

Researchers discover common markers of tumour hypoxia across 19 cancer types

Landmark pan-cancer study analyzes mutation signatures of low oxygen in more than 8,000 tumours
More

Rock the Road Raffle returns with its most valuable car to date

A 2018 Acura NSX to be prized by Prostate Cancer Canada and TADA at the AutoShow  
More


Click here for news archive